首页> Journal of controlled release : official journal of the Controlled Release Society> Mesalamine premix-based delayed release formulation and its efficacy assessment using a 3D in-vitro gut model for inflammatory bowel disease.

Mesalamine premix-based delayed release formulation and its efficacy assessment using a 3D in-vitro gut model for inflammatory bowel disease.

导出 LinkOut

翻译打印收藏纠错

第一作者： Sunil Kumar,Sah

第一单位： Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Kolkata, West Bengal 700054, India.

作者： Sunil Kumar,Sah ^[1] ; Mamta,Kumari ^[1] ; Lohare Rahul,Sanjay ^[1] ; Makka Krupali,Ashokbhai ^[1] ; Ujjwal,Gupta ^[1] ; Subhadeep,Roy ^[2] ; Santanu,Kaity ^[3]

作者单位： Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Kolkata, West Bengal 700054, India. ^[1] Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Kolkata, West Bengal 700054, India; Division of Pharmacology, Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, India. Electronic address: subhadeep@bitmesra.ac.in. ^[2] Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Kolkata, West Bengal 700054, India. Electronic address: santanu.kaity@niperkolkata.ac.in. ^[3]

关键词 3D microphysiological disease model Heterogeneous co-culture Inflammatory bowel disease Intestinal permeability Mesalamine Premix technology